{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:48:00Z","timestamp":1769845680911,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LG Chem, Ltd. (formerly, LG Life Sciences, Ltd), Mochida Pharmaceutical Co., Ltd. and Korea Health Industry Development Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1910-2","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T09:56:25Z","timestamp":1558518985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study"],"prefix":"10.1186","volume":"21","author":[{"given":"Min-Chan","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinseok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Heon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hyuk","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Yoon","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Bum","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Jae","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon-Suk","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Wuk","family":"Hur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geun-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Hee","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Joo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Cheol","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-In","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Su","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Ah","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Tomomitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonghye","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-3437","authenticated-orcid":false,"given":"Yeong Wook","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"1910_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516\u201328.","journal-title":"Ann Rheum Dis"},{"key":"1910_CR2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","volume":"77","author":"SA Bergstra","year":"2018","unstructured":"Bergstra SA, Branco JC, Vega-Morales D, Salomon-Escoto K, Govind N, Allaart CF, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis. 2018;77:1413\u201320.","journal-title":"Ann Rheum Dis"},{"key":"1910_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198\u2013206.","journal-title":"Ann Rheum Dis"},{"key":"1910_CR4","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A. Equity in Clinical Eligibility Criteria for RA treatment Working Group. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth? Ann Rheum Dis. 2014;73:2010\u201321.","journal-title":"Ann Rheum Dis"},{"key":"1910_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5639\/gabij.2012.0103-4.036","volume":"1","author":"R Haustein","year":"2012","unstructured":"Haustein R, Millas C, H\u00f6er A, H\u00e4ussler B. Saving money in the European healthcare systems with biosimilars. GaBI J. 2012;1:120\u20136.","journal-title":"GaBI J"},{"key":"1910_CR6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s12325-015-0233-1","volume":"32","author":"A Jha","year":"2015","unstructured":"Jha A, Upton A, Dunlop WCN, Akehurst R. The budget impact of biosimilar infliximab (Remsima\u00ae) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32:742\u201356.","journal-title":"Adv Ther"},{"key":"1910_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","volume":"10","author":"K Lis","year":"2014","unstructured":"Lis K, Kuzawi\u0144ska O, Ba\u0142kowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2014;10:1175\u201385.","journal-title":"Arch Med Sci"},{"key":"1910_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244\u201379.","journal-title":"Pharmacol Ther"},{"key":"1910_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/rheumatology\/41.3.329","volume":"41","author":"H Matsuno","year":"2002","unstructured":"Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA\/SCID mouse chimera. Rheumatology. 2002;41:329\u201337.","journal-title":"Rheumatology."},{"key":"1910_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1177\/106002809703101111","volume":"31","author":"KM Murray","year":"1997","unstructured":"Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) fc fusion protein (tnfr:Fc) in rheumatoid arthritis. Ann Pharmacother. 1997;31:1335\u20138.","journal-title":"Ann Pharmacother"},{"key":"1910_CR11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40265-014-0258-9","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74:1379\u2013410.","journal-title":"Drugs."},{"key":"1910_CR12","unstructured":"Han-soo L. LG Chem wins sales approval for LBEC0101 in Japan. \n                    http:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=2391\n                    \n                  . Accessed 27 Nov 2018."},{"key":"1910_CR13","unstructured":"The Center for Biosimilars Staff. Eye on Pharma: LG Chem\u2019s etanercept biosimilar gains Korean approval. \n                    https:\/\/www.centerforbiosimilars.com\/news\/eye-on-pharma-lg-chems-etanercept-biosimilar-gains-korean-approval\n                    \n                  . Accessed 27 Nov 2018."},{"key":"1910_CR14","unstructured":"Generics and Biosimilars Initiative. Guidelines for biosimilars around the world. \n                    http:\/\/www.gabionline.net\/Reports\/Guidelines-for-biosimilars-around-the-world\n                    \n                  . Accessed 9 Sept 2018."},{"key":"1910_CR15","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. CHMP\/437\/04 Rev 1. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf\n                    \n                  . Accessed 9 Sept 2018."},{"issue":"suppl_4","key":"1910_CR16","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/rheumatology\/kex277","volume":"56","author":"H Schulze-Koops","year":"2017","unstructured":"Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017;56(suppl_4):iv30\u201348.","journal-title":"Rheumatology (Oxford)"},{"key":"1910_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, Leszczy\u0144ski P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1910_CR18","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, Leszczy\u0144ski P, Porawska W, Stasiuk B, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017;76:1986\u201391.","journal-title":"Ann Rheum Dis"},{"key":"1910_CR19","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, et al. Switching from reference Adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70:832\u201340.","journal-title":"Arthritis Rheumatol"},{"key":"1910_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1910_CR21","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/acr.23586","volume":"70","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Burgos-Vargas R, Emery P, Jin B, Cronenberger C, V\u00e1zquez-Abad MD. Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res. 2018;70(11):1598\u2013606.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"1910_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40259-017-0230-9","volume":"31","author":"Heechan Lee","year":"2017","unstructured":"Lee H, Chung H, Lee S, Lee H, Yang SM, Yoon SH, et al. LBEC0101, a proposed Etanercept biosimilar: pharmacokinetics, immunogenicity, and tolerability profiles compared with a reference biologic product in healthy male subjects. BioDrugs. 2017;31:349\u201355.","journal-title":"BioDrugs"},{"key":"1910_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/annrheumdis-2017-212172","volume":"77","author":"H Matsuno","year":"2018","unstructured":"Matsuno H, Tomomitsu M, Hagino A, Shin S, Lee J, Song YW. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2018;77:488\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1910_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2377-8-38","volume":"8","author":"A Jaber","year":"2008","unstructured":"Jaber A, Bozzato GB, Vedrine L, Prais WA, Berube J, Laurent PE. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol. 2008;8:38.","journal-title":"BMC Neurol"},{"key":"1910_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/DHPS.S8495","volume":"1","author":"S Glenski","year":"2009","unstructured":"Glenski S, Conner J. 29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections. Drug Healthc Patient Saf. 2009;1:81\u20136.","journal-title":"Drug Healthc Patient Saf"},{"key":"1910_CR26","first-page":"509","volume":"42","author":"S Barlas","year":"2017","unstructured":"Barlas S. FDA guidance on biosimilar interchangeability elicits diverse views. P T. 2017;42:509\u201312.","journal-title":"P T"},{"issue":"1","key":"1910_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70(1):60\u20138.","journal-title":"Arthritis Rheumatol."},{"key":"1910_CR28","doi-asserted-by":"publisher","unstructured":"Germain V, Scherlinger M, Barnetche T, Schaeverbeke T, F\u00e9d\u00e9ration Hospitalouniversitaire ACRONIM. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of the nocebo effect. Ann Rheum Dis. 2018. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2018-214374\n                    \n                  .","DOI":"10.1136\/annrheumdis-2018-214374"},{"key":"1910_CR29","unstructured":"Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product\u2014guidance for industry: draft guidance. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM537135.pdf\n                    \n                  . Accessed 27 Nov 2018."},{"key":"1910_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, D\u00f6rner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165\u201374.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1910-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T23:21:53Z","timestamp":1589930513000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1910-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1910-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of all participating centres. All patients provided written informed consent prior to inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HM has received consulting fees for this study from Mochida Pharmaceutical Co., Ltd.; consulting fees from AYUMI Pharmaceutical Corporation and Nichi-Iko Pharmaceutical Co., Ltd.; and lecture fees from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., outside of this study. MT is an employee of Mochida Pharmaceutical Co., Ltd. SS and JY are employees of LG Chem, Ltd. All authors other than HM, MT, SS and JY received grants for this extension study from LG Chem, Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"122"}}